Back to discover

Protein / target

DNA mismatch repair protein Mlh1

Encoded byMLH1P40692Homo sapiensSwiss-Prot
Small-molecule tractable
Druggability
Structure with Ligand
6
Research papers

Protein at a glance

Biological role

ATP-dependent DNA damage sensor

Strongest disease association

Colon carcinoma

Via encoding gene MLH1 · Genetic evidence · score 0.95

Research activity

Emerging research

6 papers · latest 2025

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR).

View complete UniProt function annotation

Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis

Subcellular location

NucleusChromosome
Domains and Gene Ontology detail (21)

Gene Ontology

  • Cchiasma
  • Cchromosome
  • Clate recombination nodule
  • Cmale germ cell nucleus
  • Cmembrane
  • CMutLalpha complex
  • Cnucleoplasm
  • Cnucleus
  • Csynaptonemal complex
  • FATP binding
  • FATP hydrolysis activity
  • FATP-dependent DNA damage sensor activity

756 aa · 85 kDa · 3 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell-cycle regulationUniProt
View supporting evidence

Cell-cycle regulation

  • ·Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mi…

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene MLH1

Gene-level evidence surfaced through the gene MLH1that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Colorectal Neoplasms, Hereditary Nonpolyposis
0.97Well supported

Genetic evidence dominant · Open Targets 0.85

Colon carcinoma
0.96Well supported

Genetic evidence dominant · Open Targets 0.74

Endometrial Neoplasms
0.90Well supported

Genetic evidence dominant · Open Targets 0.64

Colonic Neoplasms
0.89Well supported

Genetic evidence dominant · Open Targets 0.68

Colorectal Neoplasms
0.87Well supported

Genetic evidence dominant · Open Targets 0.79

View evidence synthesis (5)
Colorectal Neoplasms, Hereditary NonpolyposisWell supported
0.97
agreement 0.861.00
Genetic55%Somatic mutation37%Literature8%Genetic literaturedup

Open Targets aggregate 0.85 · 3 independent evidence families · 1 not counted as duplicate

Colon carcinomaWell supported
0.96
agreement 0.851.00
Genetic81%Somatic mutation17%Literature3%

Open Targets aggregate 0.74 · 3 independent evidence families

Endometrial NeoplasmsWell supported
0.90
agreement 0.791.00
Genetic66%Somatic mutation23%Literature10%Genetic literaturedup

Open Targets aggregate 0.64 · 3 independent evidence families · 1 not counted as duplicate

Colonic NeoplasmsWell supported
0.89
agreement 0.751.00
Genetic88%Literature12%

Open Targets aggregate 0.68 · 2 independent evidence families

Colorectal NeoplasmsWell supported
0.87
agreement 0.731.00
Genetic87%Literature13%Genetic literaturedup

Open Targets aggregate 0.79 · 2 independent evidence families · 1 not counted as duplicate

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Colorectal Neoplasms, Hereditary Nonpolyposis0.85
Colorectal Neoplasms0.79
Colon carcinoma0.74
Colonic Neoplasms0.68
Endometrial Neoplasms0.64

Tractability

Small moleculesEmerging

Feasibility evidence (structure with ligand and med-quality pocket) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (5)
SM · Structure with LigandSM · Med-Quality PocketPR · UniProt UbiquitinationPR · Database UbiquitinationPR · Half-life Data

Raw Open Targets tractability assessment buckets, by modality.

Research activity

6 papers · to 2025

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Recent

Europe PMC papers linked directly to this protein.